Abstract
This discussion paper addresses the safety of HIV cure studies, particularly those involving stopping antiretroviral therapy, known as an analytic treatment interruption (ATI) in the context of the SARS-CoV-2 pandemic. More than 30 studies listed on ClinicalTrials.gov include an ATI and many others were planned to begin over the next 12 months but most were halted due to the COVID-19 pandemic. We consider the ethics, risks and practical considerations to be taken into account before re-opening HIV cure clinical trials, noting the specific risks of ATI in the context of circulating SARS-CoV-2.
| Original language | English |
|---|---|
| Article number | 100025 |
| Journal | Journal of Virus Eradication |
| Volume | 7 |
| Issue number | 1 |
| DOIs | |
| State | Published - Mar 2021 |
| Externally published | Yes |
Keywords
- Analytical treatment interruption (ATI) COVID-19
- HIV cure
- SARS-CoV-2
Fingerprint
Dive into the research topics of 'HIV cure research in the time of COVID-19 - Antiretroviral therapy treatment interruption trials: A discussion paper'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver